Chemistry Reference
In-Depth Information
[116] Reese-Wagoner, A.,
et al
., Structural properties of the adipocyte lipid binding protein.
Biochim
Biophys Acta
, 1999,
1441
, 106-116.
[117] Xu, Z.,
et al
., Crystal structure of recombinant murine adipocyte lipid-binding protein.
Biochemistry
, 1992,
31
, 3484-3492.
[118] Hanhoff, T.,
et al
., Insights into binding of fatty acids by fatty acid binding proteins.
Mol Cell
Biochem
, 2002,
239
, 45-54.
[119] Zimmerman, A. W. and Veerkamp, J. H., New insights into the structure and function of fatty
acid-binding proteins.
Cell Mol Life Sci
, 2002,
59
, 1096-1116.
[120] Boord, J. B.,
et al
., Cytoplasmic fatty acid-binding proteins: emerging roles in metabolism and
atherosclerosis.
Curr Opin Lipidol
, 2002,
13
, 141-147.
[121] Haunerland, N. H. and Spener, F., Fatty acid-binding proteins - insights from genetic
manipulations.
Prog Lipid Res
, 2004,
43
, 328-349.
[122] Jenkins-Kruchten, A. E.,
et al
., Fatty acid-binding protein-hormone-sensitive lipase interac-
tion. Fatty acid dependence on binding.
J Biol Chem
, 2003,
278
, 47636-47643.
[123] Hotamisligil, G. S.,
et al
., Uncoupling of obesity from insulin resistance through a targeted
mutation in aP2, the adipocyte fatty acid binding protein.
Science
, 1996,
274
, 1377-1379.
[124] Uysal, K. T.,
et al
., Improved glucose and lipid metabolism in genetically obese mice lacking
aP2.
Endocrinology
, 2000,
141
, 3388-3396.
[125] Binas, B.,
et al
., Requirement for the heart-type fatty acid binding protein in cardiac fatty acid
utilization.
FASEB J
, 1999,
13
, 805-812.
[126] Veerkamp, J. H.,
et al
., Structural and functional features of different types of cytoplasmic
fatty acid-binding proteins.
Biochim Biophys Acta
, 1991,
1081
, 1-24.
[127] Cohen, P., Protein kinases - the major drug targets of the twenty-first century?,
Nat Rev Drug
Discov
, 2002,
1
, 309-315.
[128] Csermely, P.,
et al
., The efficiency of multi-target drugs: the network approach might help drug
design.
Trends Pharmacol Sci
, 2005,
26
, 178-182.
[129] Morphy, R. and Rankovic, Z., Fragments, network biology and designing multiple ligands.
Drug Discov Today
, 2007,
12
, 156-160.
[130] Morphy, R. and Rankovic, Z., The physicochemical challenges of designing multiple ligands.
J Med Chem
, 2006,
49
, 4961-4970.
[131] Morphy, R., The influence of target family and functional activity on the physicochemical
properties of pre-clinical compounds.
J Med Chem
, 2006,
49
, 2969-2978.
[132] Hopkins, A. L.,
et al
., Can we rationally design promiscuous drugs?,
Curr Opin Struct Biol
,
2006,
16
, 127-136.
[133] Zartler, E. R.,
et al
., RAMPED-UP NMR: multiplexed NMR-based screening for drug
discovery.
J Am Chem Soc
, 2003,
125
, 10941-10946.
[134] Inooka, H.,
et al
., Conformation of a peptide ligand bound to its G-protein coupled receptor.
Nat Struct Biol
, 2001,
8
, 161-165.
[135] Cherezov, V.,
et al
., High-resolution crystal structure of an engineered human beta2-adrenergic
G protein-coupled receptor.
Science
, 2007,
318
, 1258-1265.
[136] Lundstrom, K., Structural genomics and drug discovery.
J Cell Mol Med
, 2007,
11
, 224-238.
[137] Vanwetswinkel, S.,
et al
., TINS, target immobilized NMR screening: an efficient and sensitive
method for ligand discovery.
Chem Biol
, 2005,
12
, 207-216.
[138] Marquardsen, T.,
et al
., Development of a dual cell, flow-injection sample holder and NMR
probe for comparative ligand-binding studies.
J Magn Reson
, 2006,
182
, 55-65.
